Neuromodulation Devices Market to Hit $14.16 Billion by 2030, Growing at a CAGR of 10.29%

Global Neuromodulation Devices Market Was Valued at USD 6.10 Billion in 2021, and It is Expected to Reach a value of USD 14.16 Billion by 2030, at a CAGR of 9.3% over the forecast period (2021–2030); Rise in Neurological Disorder and Respiratory Diseases to Fuel the Industry Growth according to strategic market research

Sambalpur, INDIA

New York, USA, Sept. 05, 2022 (GLOBE NEWSWIRE) -- The Worldwide Neuromodulation Devices Market value was USD 6.10 Billion in 2021 and will reach USD 14.16 Billion in 2030 with a 10.29% CAGR. Neuromodulation refers to the process of modifying, regulating, or therapeutically altering electrical or chemical activities in the central, peripheral, or autonomic nervous systems. Several factors expediting the market growth are the continuous rise in neurological disorder cases, respiratory problems, the rise of funding by the government for the technological developments of neuromodulation devices, etc. 

To get a first-hand overview of the report, Request a Sample at

Neuromodulation Devices Market Insights: 

  • The Spinal-Cord Stimulators segment significantly dominated with a share of 40.78% for the Product Type sector. 
  • The Parkinson's disease segment of the Application section dominated comprehensively with a share of 30.12%.
  • For the End-User section, the ASCs and Hospital segment dominated with a share of 81.23%.
  • For the Regional section, North America dominated with a 45.22% market share.  

Factors expediting the Neuromodulation Devices Market Growth

(Increasing cases of neurological disorders, respiratory problems, and substantial funding by the government towards the technological developments of neuromodulation devices are fuelling its growth rate worldwide)

  • A continuous surge in the increasing number of neurological disorders worldwide is the main reason augmenting the market growth. WHO reported that nearly 1.1 Billion people (i.e., around 13.75% of the worldwide population) are currently suffering from neurological disorders ranging from Parkinson's disease to Alzheimer, sclerosis, stroke, migraine, etc. SMR's study revealed that Ischemic Strokes are the most common neurological disorder all over the world. Almost 87% of the total strokes that occur worldwide are ischemic type strokes.

  • Apart from the increase in neurological disorders, the rising number of cases of respiratory problems is expediting the market growth. NCBI reported that currently, around 545.44 million people worldwide (i.e., almost 7.41% of the world's population) are suffering from NCDs or chronic respiratory diseases. Furthermore, the rise in investments by governments towards the technological advancements of neuromodulation devices is augmenting the market growth extensively. 

Neuromodulation Devices Market: A thorough Segmentation Analysis

The worldwide Neuromodulation Devices Market segmentation has been performed based on Product Type, Application, End-User & Geography. 

For Product Type:

  • Spinal Cord Stimulators
  • Deep Brain Stimulators
  • Vagus Nerve Stimulators
  • Sacral Nerve Stimulators
  • Transcranial Magnetic Stimulators
  • Others

For Application 

  • Chronic Pain
  • Parkinson's Disease
  • Epilepsy
  • Migraine
  • Depression
  • Tremor
  • Faecal and Urinary Incontinence 
  • Others

For End-User 

  • Hospitals
  • ASCs
  • Clinics
  • Others 

For Geography

  • Canada
  • United States
  • Mexico
  • Rest of North-America


  • Australia
  • Japan
  • Vietnam
  • South Korea
  • Singapore
  • China
  • India
  • Rest of Asia-Pacific

Europe Continent

  • Greece
  • Poland
  • Italy
  • UK
  • Finland
  • Portugal
  • Netherlands
  • Germany
  • Russia
  • France
  • Rest of the Europe 


  • Saudi Arab
  • Argentina
  • Kuwait
  • Brazil
  • Qatar
  • South Africa
  • Algeria
  • UAE

Make a Direct Purchase of the latest Neuromodulation Devices Market Report published in the month of July 2022. Click the below link to initiate the purchase:

The Spinal-Cord Stimulators segment significantly dominated with a share of 40.78% for the Product Type sector due to its growing usage in the treatment of nerve and chronic pain. As per the International Neuro-Modulation Society, each year, almost 34k patients worldwide undergo spinal surgery by means of spinal-cord stimulators. Additionally, according to the CDC, in 2021, an estimated 20.4% (50.0 million) individuals in the USA suffered from chronic pain, of which 8.0% (19.6 million) were suffering from serious chronic conditions.

The Parkinson's disease segment of the Application section dominated comprehensively with a share of 30.12%. Parkinson's disease is a long-lasting neurodegenerative brain condition that impairs movement. GBD/Global Burden Diseases Survey reported that in 2020, approximately 6.21 million people worldwide suffered from Parkinson's disease. 

For the End-User section, the Hospitals segment dominated the market with a share of 81.23%. For patients with neurological problems, hospitals offer highly-efficient implanted device therapies and neuromodulation surgeries. Spinal cord stimulation is the most common neuromodulation therapy offered by hospitals to the patients suffering from neurological diseases. SMR's research studies figured out that each year around 50k spinal-cord stimulators are implanted around hospitals worldwide.

For the Regional section, North America dominated with a 45.22% market share. Continuous rising cases of people suffering from neurological disorders is increasing the demand for neuromodulation devices in this region. SMRs research survey delineated that currently, around 25 million Americans have neurological disorders, out of which Huntington's disease & amyotrophic lateral sclerosis are regarded as the most common diseases, followed by frontotemporal dementia, myasthenia gravis, etc.

Pivotal players of the Neuromodulation Devices Market:

  • Medtronic PLC
  • Boston Scientific Corp
  • LivaNova
  • Abbott 
  • Nevro Corp
  • NeuroSigma,
  • Synapse Biomedical.
  • Neuronetics
  • NeuroPace
  • Bioness
  • BioControl Medical
  • Integer Holdings Corp
  • Soterix Medical

Before initiating a purchase, make a Pre-order enquiry and get a detailed overview of the content of the report.

Report CoverageDetails
Forecast Period2021-2030
Forecast Period 2021 to 2030 CAGR10.28% 
2030 Value Projection$14.17 Billion
Base Year2020 
Market Size in 2021$6.09 Billion
Historical Data for2015-2019
No. of Pages135 
CompaniesMedtronic, Boston Scientific Corporation, Abbott Laboratories, LivaNova, Synapse Biomedical, Nevro Corporation, NeuroSigma, Inc., NeuroPace, Inc., Neuronetics, Inc., BioControl Medical, Bioness, Soterix Medical, Integer Holdings Corporation, Bioinduction, GiMer Medical, GTX Medical, Helius Medical Technologies, MicroTransponder, Neuronano, BlueWind
Leading Segment Based on Componentpain management
 Leading Region North America
Segments CoveredBy Component Outlook, By Sports, and By Region

Recent Developments

  • On August 23rd, 2022, Abbott launched its brand new Proclaim Plus SCS system to enhance the level of efficacy of its neuromodulation therapies. The system is designed based on the concept of BurstDR stimulation, which works by imitating natural patterns that are found in the brain to deliver pain relief therapy. Moreover, this method of using the concept of BurstDR stimulation has been preferred by almost 87% of patients worldwide till date. 

  • On July 12th, 2022, the first neuromodulation device in the world to receive FDA approval, the Barostim Programmer, was introduced by CVRx, to treat various signs and symptoms of heart failure. This second-generation Barostim programmer has a very advanced cellular network and incorporates a highly sophisticated user interface that aids in streamlining IPG programming.

  • On July 5th, 2022, Orchestra BioMed and Medtronic joined hands to develop a highly advanced cardiac neuromodulation therapy, BackBeat CNT. It is created in such a manner that it works automatically without any reliance on patient compliance and is integrated with a variety of antihypertension medications. Additionally, it is easily adaptable to cardiac rhythm control devices, such as pacemakers, using a conventional implant and lead implantation methods.

 To read the summary of the report, visit the website at

Related Reports

Neurovascular Devices
The report on Neurovascular Devices Market crafted by SMR delineates its variety of restraints, opportunities, challenges, etc. The Neurovascular Devices Market worth was USD 2.81 Billion in 2021 and will reach USD 5.92 Billion in 2030 with an 8.21% CAGR. The factors fuelling its growth rate are the rise in expenditure by the governments worldwide on R&D activities because of the rising cases of neurological diseases. Key players prevailing in the market are Medtronic, Stryker, Penumbra, Johnson & Johnson, etc.

Neuroendoscopy Devices
SMR's Neuroendoscopy Devices Market Report deciphers a 360-degree idea regarding its drivers, opportunities, challenges, etc. The Neuroendoscopy Devices Market value was USD 186.99 Million in 2021 and will reach USD 314.31 Million in 2030 with a 5.93% CAGR. Factors enhancing its growth are increased need for MI surgeries, rising occurrence of various neurological problems worldwide, etc. Key market players operating here are Clarus Medical, Schindler, LocaMed, Karl Storz, Machida, Evonos, etc.

Neurostimulation Devices 
The Neurostimulation Devices Market Report publicized by SMR elucidates a brief idea about its challenges, opportunities, restraints, etc. The Neurostimulation Devices value in 2021 was USD 4.79 Million in 2021 and will reach USD 50.71 Million in 2030 with a 12.81% CAGR. Factors proliferating its growth are the rise in cases of Parkinson’s diseases, increase in geriatric netizen population, rise in NCD/chronic diseases, etc. Some notable players prevailing in this market are Nevro Corp, Boston Scientific, Cyberonics, Medtronic, Aleva Therapeutics, Neutronics, ElectroCore, etc.

About Us:
Strategic Market Research facilitates the organizations globally in taking pivotal business decisions by furnishing the Syndicated and Customized Research Reports, which are highly precise in terms of market numbers. We believe that every firm, whether it is a startup which is in the Introduction stage of the Product Life cycle or an established one which is at the growth stage, requires market research services in order to streamline its key business blueprint. It may be related to Product Launch, Go to Market strategies, Competitive Analysis or new geographical penetration and expansion.

Contact Us:
Strategic Market Research LLP.
Sunil Kumar 
India: +91-8260836500
Press Release:

Connect Us: